{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal stem Multiple Sclerosis",
            "NStudiesAvail": 430108,
            "NStudiesFound": 38,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 38,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Hamid Gourabi, PhD",
                              "Nasser Aghdami, MD,PhD",
                              "Masoud Nabavi, MD",
                              "Leila Arab, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair",
                              "Study Director",
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "evaluate the effect of mesenchymal stem cell transplantation on number of GD positive lesions.",
                              "evaluate the effect of mesenchymal stem cell transplantation to improve brain atrophy",
                              "evaluation the effect of mesenchymal stem cell transplantation on number of sever relapses",
                              "Evaluation the effect of mesenchymal stem cells on progression of disease based on EDSS",
                              "Evaluation the effect of mesenchymal stem cells transplantation on MSFC"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "MRI metrics changes",
                              "Brain atrophy",
                              "number of sever relapses",
                              "EDSS",
                              "MSFC"
                        ],
                        "NCTId": [
                              "NCT01377870"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse events is defined as any untoward or undesirable medical occurence in the form of signs, symptoms, abnormal findings or diseases that emerge during the study period, regardless of causal relationship to the study drug.",
                              "Brain MRI examination"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To evaluate number of participants with an adverse event related to the treatment.",
                              "To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions."
                        ],
                        "NCTId": [
                              "NCT03778333"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Dimitrios Karussis, Prof."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2009"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Appearance of adverse events during the 1-4 years of follow up after one or multiple treatments with MSC"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis"
                        ],
                        "NCTId": [
                              "NCT00781872"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Giancarlo Comi, MD",
                              "Bruno Bonetti, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence and severity of adverse events in MSC treatment group compared to placebo group.",
                              "total number of contrast-enhancing lesions (GEL) at MRI scan"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety",
                              "efficacy"
                        ],
                        "NCTId": [
                              "NCT01854957"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary objective of the study is to assess the safety of IV therapy with autologous MSCs in MS. Number of participants with adverse events will be documented at week 0,4,8,12,16,20,24,28,32,36,40,44,48 post treatment. Co-primary objective of the study is to evaluate the activity of autologous MSCS in MS patients, in terms of reduction as compared to placebo in the total number of contrast-enhancing lesions (GEL) at MRI acquired on conventional 1,5 T MRI scans over 24 weeks."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients."
                        ],
                        "NCTId": [
                              "NCT01730547"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Abdallah Awidi, MD.",
                              "Said Dahbour, MD."
                        ],
                        "OverallOfficialRole": [
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Assessing the safety of autologous Mesenchymal Stem Cells injection"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The number of patients with any relevant side effects observed"
                        ],
                        "NCTId": [
                              "NCT01895439"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Albert Saiz, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The coprimary endpoints were safety and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study"
                        ],
                        "NCTId": [
                              "NCT01228266"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Score of Expanded Disability Status Scale (EDSS)"
                        ],
                        "NCTId": [
                              "NCT01364246"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Clanet Michel, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety assessed by number, timeframe of occurrence and severity of Adverse Events",
                              "total number of contrast-enhancing lesions (GEL) at MRI scan"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of MSCs infusion, number, timeframe of occurrence and severity of Adverse Events",
                              "efficacy: number of contrast-enhancing lesions (GEL) at MRI scan"
                        ],
                        "NCTId": [
                              "NCT02403947"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Jorge Paz-Rodriguez, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse events"
                        ],
                        "NCTId": [
                              "NCT02034188"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Dimitrios Karussis, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 1, 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To evaluate the safety and tolerability of MSCs repeated treatment in progressive MS patients",
                              "To evaluate the changes in Expanded Disability Status Scale (EDSS) score after repeated MSC treatments compared to run-in period."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Appearance of adverse events",
                              "The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)"
                        ],
                        "NCTId": [
                              "NCT04823000"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Siddharthan Chandran, MBChB, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events"
                        ],
                        "NCTId": [
                              "NCT00395200"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Cristina Ramo, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Physical examination, vital signs (HR, RR, BP, axillary temp), analytical results (biochemistry, hematology,) electrocardiographic monitoring, pulse oximetry and adverse events.\nClinical worsening both new relapses or disability measured by Expanded Disability Status Scale (EDSS), until the end of the study.",
                              "- Cumulative number of MRI Gd-enhancing lesions (3 and 6 months post-treatment)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change from baseline in safety",
                              "Change from baseline in effectiveness by MRI"
                        ],
                        "NCTId": [
                              "NCT02035514"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Oscar Fernandez Fernandez, MD, PhD",
                              "Guillermo Izquierdo Ayuso, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells"
                        ],
                        "NCTId": [
                              "NCT01056471"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Paolo A Muraro, MD PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The number,time-frame and severity of adverse events in the stem cell treatment group will be compared to the placebo group.",
                              "To evaluate the efficacy of autologous mesenchymal stem cells in MS patients, quantified by the reduction in the number of new contrast-enhancing lesions on MRI scans over 24 weeks and the total number of GEL counted over months 1, 3 and 6 will be compared between treatment groups."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Frequency, Timing and Severity of Adverse events in MSC and placebo groups as Assessed by CTCAE v4.0",
                              "Total number of GELs at weeks 4, 12 and 24 after MSC therapy"
                        ],
                        "NCTId": [
                              "NCT01606215"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Christopher Elnan Kvistad, PhD",
                              "Lars B\u00f8, Prof"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 4, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Somatosensoric evoked potentials (SEP) + visual evoked potentials (VEP) + motor evoked potentials (MEP), latency (ms) and amplitude (mV)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Neurophysiological parameters - Combined evoked potentials"
                        ],
                        "NCTId": [
                              "NCT04749667"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Saud A Sadiq, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary objective of the study is to assess the safety and tolerability of intrathecal therapy with autologous MSCNPs in MS. Number of participants with adverse events will be documented 1 day, 1 week, 1 month and 2 months post treatment for three treatments (followup for third treatment is 3 months instead of 2 months).",
                              "The co-primary objective will be to observe long term safety of the treatment 6 months and 30 months following the last treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse events",
                              "Number of participants with adverse events ."
                        ],
                        "NCTId": [
                              "NCT01933802"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Saud A Sadiq, MD, FAAN"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Changes in disability assessed based on composite score of EDSS, timed 25-foot walk (T25FW), and nine hole peg test (9HPT) (EDSS-Plus). Improvement will be defined by at least one of the following three measures: \u22650.5 improvement in EDSS (if EDSS at entry is \u2265 6.0) or \u2265 1.0 improvement in EDSS (if EDSS at entry is \u22645.5), \u226520% improvement in T25FW, and \u226520% improvement in 9HPT in either dominant or non-dominant upper limb. Assessments will be made at baseline, Month 6, 13, 20, 27 & 36 in each group."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Expanded Disability Status Scale (EDSS) Plus"
                        ],
                        "NCTId": [
                              "NCT03355365"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Chadwick Prodromos, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Clinical monitoring of possible adverse events or complications"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety (adverse events)"
                        ],
                        "NCTId": [
                              "NCT05003388"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Woei C Shyu"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2026"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "SAE, SUSAR, and AE incidences over the study period",
                              "CFB of EDSS to Visit 10"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Primary Endpoint for Phase I portion",
                              "Primary Endpoint for Phase IIa portion"
                        ],
                        "NCTId": [
                              "NCT05532943"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Louis A Cona, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 18, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "incidence and nature of adverse events, serious adverse events, or any unanticipated adverse events. The nature, incidence, and rate of adverse events will be assessed",
                              "Multiple Sclerosis Impact Scale (MSIS-29)",
                              "Modified SF-36 for Cell-Based Therapy Follow Up",
                              "Vital signs of sitting blood pressure, temperature and heart rate"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Standard Complication Questionnaire",
                              "MS Impact Scale - MSIS-29",
                              "Modified SF-36 Cell-Based Therapy Follow Up",
                              "Physical Evaluation"
                        ],
                        "NCTId": [
                              "NCT02326935"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Abdallah Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 25, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To isolate stem cells from UC: first, the cord will be cut into small pieces around (4-5cm) and washed with phosphate buffered saline, then the umbilical vein and the two arteries will be removed.These pieces will be placed in culture plate and cultured in UC-MSCs medium consist of; alpha modification of Minimum Essential Medium (\u03b1-MEM) supplemented with 10% fetal bovine serum, 1% glutamine, 1% penicillin/streptomycin and 1 \u03bcg/mL amphotericin B.After incubation period the undigested tissue will be discarded and nucleated cells will be pelleted by centrifugation at 450xg for 10 minutes. Cell pellet will be re-suspended in UC-MSCs culture medium, cultured in tissue culture flasks and placed in CO2 incubator at 37\u00b0C, 5% CO2. Cells will be expanded in multilayer cell factory tissue culture flasks to reach an estimated 108 UC-MSCs that will be frozen in bags of 106 cells for subsequent thawing and administration."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Isolation and Expansion of Mesenchymal Stem Cells"
                        ],
                        "NCTId": [
                              "NCT03326505"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Jeffrey A Cohen, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS"
                        ],
                        "NCTId": [
                              "NCT00813969"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "Mark S. Freedman, MSc MD FRCPC"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence and severity of adverse events in MSC treatment group compared to placebo group",
                              "Total number of gadolinium-enhancing lesions (GEL) on MRI scan"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety",
                              "Efficacy"
                        ],
                        "NCTId": [
                              "NCT02239393"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Saud A Sadiq, MD, FAAN"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Temporarily not available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT03822858"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [
                              "Dr. Bill Brashier, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline.\n\nClinical improvement is defined as decrease in Expanded Disability Status Scale (EDSS) score greater than 0.5 from baseline."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline"
                        ],
                        "NCTId": [
                              "NCT02587715"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Dr. Bill Brashier, M.D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline (Time Frame: 12 months). Clinical improvement is defined as decrease in Expanded Disability Status Scale (EDSS) score greater than 0.5 from baseline."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Proportion of patients with clinical improvement in EDSS score compared to baseline"
                        ],
                        "NCTId": [
                              "NCT02418325"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Hadas Lemberg, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 15, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The proportions of the patients in the three treatment-groups (MSC-IV, MSC-IT and placebo) who experienced any adverse event.",
                              "The proportions of the patients with treatment failure (increase of the EDSS by 1 point for patients with baseline values of 5.0 or less and of 0.5 degree for baseline EDSS of more than 5.0), confirmed by two consecutive evaluations, in the three treatment-groups."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety Assessment",
                              "Neurological efficacy"
                        ],
                        "NCTId": [
                              "NCT02166021"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [
                              "Djamchid Lotfi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 22, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The MSQOL-54 is a comprehensive health-related quality of life measure incorporating general and MS-specific questions into a single instrument.\n\nThe developers used the SF-36 as a base and added 18 questions to address MS-specific problems, including fatigue and cognitive function.\n\nThis 54-item questionnaire provides 12 sub-scales, two summary scores, and two extra single-item measures. The sub-scales are physical function, role limits-physical, emotional role restrictions, pain, emotional well-being, energy, health perceptions, social position, cognitive function, health distress, overall quality of life, and sexual function. There is no single overall score for MSQOL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores (scale scores range from 0 to 100 and a higher scale score indicates improved quality of life)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument."
                        ],
                        "NCTId": [
                              "NCT05116540"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Guillermo Izquierdo, MD",
                              "Eduardo Ag\u00fcera, MD",
                              "Victoria Fern\u00e1ndez, MD",
                              "Inmaculada Concepci\u00f3n Herrera, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator",
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image"
                        ],
                        "NCTId": [
                              "NCT01745783"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [
                              "Xavier Montalban, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 27, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety profile"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events"
                        ],
                        "NCTId": [
                              "NCT02495766"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [
                              "Richard Kim, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2027"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Frequency of treatment-emergent adverse events (TEAEs).",
                              "Clinically significant laboratory abnormalities."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety and tolerability",
                              "Safety and tolerability"
                        ],
                        "NCTId": [
                              "NCT04956744"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Jeffrey Cohen, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 11, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety of 3 intrathecal doses of NurOwn\u00ae (MSC-NTF cells)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of treatment-emergent adverse events"
                        ],
                        "NCTId": [
                              "NCT03799718"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Effectiveness assessment by MRI",
                              "Safety assessment by physical examination, vital signs, analytical results, electrocardiograph monitoring, and Expanded Disability Status Scale (EDSS)"
                        ],
                        "NCTId": [
                              "NCT03069170"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [
                              "Fu-Dong Shi, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Compare EDSS change before and one year after mesenchymal stem cells (MSC) infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "EDSS"
                        ],
                        "NCTId": [
                              "NCT02249676"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [
                              "Dimitrios Karussis, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To evaluate the safety of 4 successive intrathecal administrations of autologous MSC cells administered every three months in ALS patient.\n\nPatients will be follow-up every 3 months for change in their neurological status and the incidence of adverse events. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0",
                              "Degree of change in the rate of progression (calculation of monthly change in ALSFRSr score: 0-48, higher scores are better) between the run-in period to 3 months post last MSC-injection"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period",
                              "Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr"
                        ],
                        "NCTId": [
                              "NCT04821479"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [
                              "Mohamad Bydon, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The ASIA Impairment Scale describes a person's functional impairment (both motor and sensory) as a result of their spinal cord injury. The scale has 5 levels, ranging from A (complete) to E (normal)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "\u2022Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)"
                        ],
                        "NCTId": [
                              "NCT04520373"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "mRSS score,HRQOL score, SF-36 score for SSc patients"
                        ],
                        "NCTId": [
                              "NCT00962923"
                        ]
                  }
            ]
      }
}